Pediatric EBV Positive Mucocutaneous Ulceration in Stomach a Rare Entity

ALAKAYA M., Gundogan B. D., ARSLANKÖYLÜ A. E., KARABULUT Y. Y., AKYÜREK N., Karhan A. N., ...Daha Fazla

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, cilt.44, sa.2, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 44 Sayı: 2
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1097/mph.0000000000002250
  • Dergi Adı: JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE
  • Anahtar Kelimeler: Epstein Barr virus, Epstein Barr virus positive mucocutaneous ulceration, brentuximab vedotin, BRENTUXIMAB VEDOTIN, LYMPHOPROLIFERATIVE DISEASE, HODGKINS LYMPHOMA, CELL LYMPHOMA, PHASE-2, MULTICENTER
  • Gazi Üniversitesi Adresli: Evet

Özet

Epstein Barr virus (EBV) related lymphoproliferative diseases may occur in immunocompromised patients or patients with a history of drug use causing immunodeficiency. EBV positive mucocutaneous ulceration in the new classification of lymphoproliferative diseases in 2016 is very rare in children. Involvement occurs in the skin, oral mucosa, and gastrointestinal system. Gastric involvement is very rare in the literature. There is no case of gastric involvement in children. There are no specified modalities in the treatment of EBV positive mucocutaneous ulceration. We presented our pediatric patient with ataxia telangiectasia who presented with abdominal pain and difficulty swallowing and diagnosed with EBV positive mucocutaneous ulceration in the stomach. We started brentuximab vedotin during the treatment process, and complete remission was achieved after 6 cures of treatment. Our patient is the first case of EBV positive mucocutaneous ulceration in the pediatric case series.